ClinicalTrials.gg
Not yet recruitingNCT07944105Updated Nov 18, 2026

SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS).

A Phase 1/2 interventional study of ZEN003694 and Radiation Therapy in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by M.D. Anderson Cancer Center · Phase 1/2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 56 studies in Histiocytoma, Malignant Fibrous with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. Histiocytoma, Malignant Fibrous · United States.

Planned enrollment
23rd of 52
57 · median 54
Started
2027
the only one that year
Phase 1/2
6 of 56
1 open now
Primary completion
2030-12
later than 8 of 10 live
Registered
56th of 56
by date
Lead sponsor
5 of 56
M.D. Anderson Cancer Center

Among the 56 studies in Histiocytoma, Malignant Fibrous with a site in United States, this one is the 23rd largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 1/2, reaches primary completion later than 8 of the 10 other live ones, and was the 56th registered.

Histiocytoma, Malignant Fibrous

91 studies on the registry are indexed under Histiocytoma, Malignant Fibrous; 15 are open to participants now.

Browse Histiocytoma, Malignant Fibrous studies →

Open to participants now

6 of the 56 studies in Histiocytoma, Malignant Fibrous with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Histiocytoma, Malignant Fibrous studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Histiocytoma, Malignant Fibrous with a site in United States, or all of them as a file.
02

Study summary

This is a single-center, Phase 1/2 clinical trial evaluating the safety, tolerability, RP2D, and preliminary efficacy of ZEN003694 in combination with RT in patients with metastatic UPS and MFS who have completed first- or second- line doxorubicin-based chemotherapy without disease progression.

Read the detailed description

Primary Objective:

To evaluate the objective response rate (ORR) according to RECIST v1.1 at 12 weeks in patients treated with ZEN003694 and RT following first- or second- line doxorubicinbased chemotherapy compared to standard of care approach of surveillance.

Secondary Objectives:

  • To estimate PFS following treatment with ZEN003694 and RT after first- or second- line doxorubicin-based chemotherapy.
  • To estimate the 12-month local control rate and time to local recurrence in primary and metastatic irradiated lesions local control rate.
  • To estimate OS following treatment with ZEN003694 and RT after first- or second- line doxorubicin-based chemotherapy.
  • To characterize the safety profile of ZEN003694 in combination with RT following first- or second- line doxorubicin-based chemotherapy using CTCAE v6.0.
  • Key secondary translational objective: To characterize treatment-induced changes in the tumor microenvironment using paired tumor biopsies obtained at baseline and Week 12/EOT, including changes in DNA damage, immune-cell infiltration, antigen presentation, and PD-L1 expression.

Exploratory Objective:

We will perform exploratory analyses on tumor biopsy and blood samples collected at baseline and post-treatment at the indicated time points to identify potential predictive biomarkers of response. These may include immunohistochemistry (IHC)-based quantification of g-H2AX foci (as surrogate for degree of DNA damage induced by the treatment), tumor-associated antigens and neoantigens, tumor-infiltrating lymphocytes (TILs), tumor PD-L1 expression, and circulating tumor DNA (ctDNA) analysis.

03

Conditions studied

  • Undifferentiated Pleomorphic Sarcoma
  • Myxofibrosarcoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease Characteristics

  • confirmed Stage IV UPS/MFS. Pathologic terms may include pleomorphic undifferentiated sarcoma, unclassified spindle cell sarcoma, spindle cell sarcoma not otherwise specified, pleomorphic spindle cell sarcoma, or pleomorphic fibroblastic sarcoma.

    • Patients must have completed at least 4 and no more than 6 cycles of doxorubicin-based first or chemotherapy (single agent or in combination) at least 4 weeks out and within 12 weeks prior to enrollment and have not experienced progressive disease documented per 1.1 since starting doxorubicin for this current episode of sarcoma.
  • Patients must have by RECIST 1.1. Previously ablated/ radiated/treated areas can only be counted towards measurable disease if there is unequivocal progression after directed therapy. Patients must have at least one lesion amenable safely to radiotherapy on trial AND at least one other lesion which is measurable per RECIST 1.1.
  • Participant will have tumor lesion(s) or metastases amenable to , excluding bone metastases, as confirmed by a radiologist, if appropriate, and as deemed safe by the Investigator. If there is only one target lesion per RECIST 1.1 which is accessible to biopsy, this lesion should be at least 2cm. 2) Patients Characteristics
  • Age ≥18 years.
  • performance status ≤2 ( ≥60%,).
  • of >3 months, as determined by the investigator.
  • Ability to swallow and retain oral medication.
  • Ability to understand and the willingness to sign a written document and comply with study procedures.

    3) Concurrent Cancer Participants with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial 4) Organ and Marrow Function Requirements

Patients will have adequate organ and marrow function as defined below:

≥ 8 g/dL. ≥1,300/mcL ≥100,000/mcL Total ≤ 1.5 x institutional (ULN) (except patients with Gilbert's syndrome, who must have total bilirubin \< 2 x institutional ULN ) (SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN for age Calculated ≥ 50 mL/min (via eGFR) 5) CNS and Cardiac Requirements

  • Participants with treated are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and has been clinically stable for at least 1 month.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients with such risk should be class 2B or better.
  • Patients should not have a >450 msec or history of torsades de pointes or history of congenital long QT syndrome. Reproductive/ Requirements The effects of ZEN003694 on the developing human fetus are unknown. For this reason and because agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy UT MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:

    • (no menses in greater than or equal to 12 consecutive months).
    • History of hysterectomy or bilateral salpingo-oophorectomy.
    • Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
    • History of bilateral tubal ligation or another surgical sterilization procedure.
  • Men and women treated or enrolled on this protocol must be surgically sterile or if sexually active with a female partner of child-bearing potential, participants must agree to use two methods of birth control (1 of which must include a condom as a barrier method of contraception) from screening through 4 months after the last dose of ZEN003694.
  • Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent Treatments and Agents

    • Prior BET-targeted therapy for sarcoma.
    • Patients who are receiving any other investigational agents or have received any other investigational agent within 3 weeks prior to enrollment.
    • Treatment with a bone-targeted radionuclide within 6 weeks of first administration of study drug.
    • Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A of at least 14 days is required between end of radiotherapy and initiation of treatment on trial.
    • Participants requiring strong inhibitors or strong inducers of enzymes, as well as sensitive substrates of CYP3A3, CYP1A2 and CYP2C19 are ineligible. Strong inhibitors of CYP3A4 must be discontinued for at least 7 days and strong CYP3A inducers at least 14 days or 5 half-lives prior to the first dose of ZEN003694 and throughout the study.
    • Acid reducing agents (PPI, H2 blockers and antacids) may alter the pharmacokinetics of ZEN003694 by reducing ZEN003694 exposure. Participants receiving proton pump inhibitors (PPI) are ineligible. Avoid H2 blockers or antacids 10 to 12 hours before and 2 hours after ZEN003694 administration. Stagger the dosing of ZEN003694 and an antacid by at least 2 hours.

      • Received medications known to prolong within 5 half-lives before the first dose of the study treatment. List of medications that prolong QTc can be obtained from micromedex or Lexidrug
    • Administration of a within 28 days of starting study treatment and for up to 1 month after the final dose of study treatment or anticipation that such vaccine will be required during the study. Note: mRNA-based vaccines for COVID-19 are allowed as well as inactivated flu vaccines.
    • Has had or is scheduled to have major surgery \<28 days prior to the first dose of study treatment.
  2. Other comorbidities affecting participation

    • Evidence of severe or uncontrolled systemic disease or psychiatric illness that, in the investigator's judgment, would limit safety or compliance.
    • Historically positive for (HIV) (screening test for HIV not required in the USA); or known active defined as positive HBV DNA viral load or as defined by related guidelines (CDC guidelines in the USA); or virus (HCV) unless previously treated and viral load is undetectable. HBV and HCV tests are not required as part of the screening if patient has no history of hepatitis B or C or risk factors of exposure.
    • Participants with bleeding disorder or taking coumadin. Use of direct oral anticoagulants (DOAC) (e.g. apixaban, rivaroxaban) and low molecular weight heparin is allowed.
    • Other co-morbidities, such as uncontrolled pulmonary disease, active central nervous system disease, active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy, or any other condition that could compromise safety or the patient's participation in the study.
    • Impairment of gastrointestinal function that may significantly alter the absorption of ZEN003694.
    • Any condition which, in the opinion of the investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (estimated)

Study arms

  • Experimental
    Phase 1 Dose Escalation: Treatment with ZEN003694 + RT

    Drug: ZEN003694 · Drug: Radiation Therapy

  • Experimental
    Phase 2 Randomized Expansion Arm A: Treatment with ZEN003694 + RT

    Drug: ZEN003694 · Drug: Radiation Therapy

  • Experimental
    Phase 2 Randomized Expansion Arm B: Observation

    Drug: ZEN003694

  • Experimental
    Phase 2 Randomized Expansion Arm C: Treatment with ZEN003694 Alone

    Drug: ZEN003694

Interventions

  • DrugZEN003694

    Given orally once daily

    Also known as: ZEN-3694

  • DrugRadiation Therapy

    The radiation therapy is to be delivered using a linear accelerator or proton gantry.

    Also known as: Radiotherapy

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    ncidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 6.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2027; primary completion for Dec 2030, 43 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 18, 2026
StartEst.
May 31, 2027
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944105
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
May 31, 2027 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Michael Nakazawa, MD, PHD
Contact
msnakazawa@mdanderson.org
346-725-4509
Michael Nakazawa, MD, PHD
principal investigator · UT MD Anderson

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion